These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6879880)

  • 1. Therapeutic efficacy of salvage cystectomy. Do results reflect natural history of bladder cancer?
    Droller MJ; Walsh PC
    Urology; 1983 Aug; 22(2):118-22. PubMed ID: 6879880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of regionally advanced bladder cancer. An overview.
    Droller MJ
    Urol Clin North Am; 1992 Nov; 19(4):685-93. PubMed ID: 1441025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radical cystectomy in the treatment of bladder cancer always in due time?].
    May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
    Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle-invasive bladder tumour: can the bladder be preserved?
    Sella A
    BJU Int; 2008 Nov; 102(9):1053-4. PubMed ID: 18715247
    [No Abstract]   [Full Text] [Related]  

  • 7. Radical radiotherapy and salvage cystectomy for T2/3 cancer of the bladder.
    Blandy JP; Jenkins BJ; Fowler CG; Caulfield M; Badenoch DF; England HR; Hope-Stone HF; Mair GM; Mantell BS; Oliver RT
    Prog Clin Biol Res; 1988; 260():447-51. PubMed ID: 3129734
    [No Abstract]   [Full Text] [Related]  

  • 8. Conservative management of muscle-infiltrating bladder cancer: prospective experience.
    Herr HW
    J Urol; 1987 Nov; 138(5):1162-3. PubMed ID: 3669160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
    May M; Nitzke T; Helke C; Vogler H; Hoschke B
    Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [T1G3 bladder tumors].
    Dormia G; Minervini MS; Malagola G; Bertana F; Luongo P; Mazza L; Gonnella G; Longo G; Castellani R
    Arch Ital Urol Androl; 1996 Feb; 68(1):29-32. PubMed ID: 8664917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy and follow-up of bladder cancer].
    Meyer D; Schmid HP; Engeler DS
    Wien Med Wochenschr; 2007; 157(7-8):162-9. PubMed ID: 17492413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the clinical target volume for bladder cancer radiotherapy treatment planning.
    Jenkins P; Anjarwalla S; Gilbert H; Kinder R
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1379-84. PubMed ID: 19394154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin.
    Fukumoto K; Kikuchi E; Mikami S; Miyajima A; Oya M
    BMC Urol; 2016 Jan; 16():5. PubMed ID: 26785916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary adenocarcinoma of urinary bladder.
    Nocks BN; Heney NM; Daly JJ
    Urology; 1983 Jan; 21(1):26-9. PubMed ID: 6823700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder cancer: natural history, tumor markers, and early detection strategies.
    Foresman WH; Messing EM
    Semin Surg Oncol; 1997; 13(5):299-306. PubMed ID: 9259085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.